$37,485,000

Department of Health and Human Services·Office of Assistant Secretary for Preparedness and Response

WORK BEGAN2025-09-26·LATEST ACTION2026-03-17·SOURCEUSASPENDING·SOURCE IDCONT_AWD_75A50325F80036_7505_36F79723D0219_3600

Award description

PROCURENT OF XOFLUZA (BALOXAVIR MARBOXIL) 40MG AND 80MG TABLETS

Verbatim from USAspending.gov. Capitalization, abbreviations, and codes are unchanged.

The Buildout's read

What the model surfaced from this award

Confidence: high

In plain English

Procurement of Xofluza antiviral tablets for federal stockpile or emergency preparedness by HHS.

Sub-sectors

antiviral-procurementpandemic-preparednessbaloxavir-marboxil

Why this matters

Baloxavir marboxil is a rapid-acting influenza antiviral; stockpiling supports pandemic/epidemic response capacity.

Supply-chain signal

Large-scale procurement from Genentech signals demand for domestic antiviral manufacturing and distribution readiness.

U.S.–China competition angle

Securing U.S. antiviral supply chains reduces dependence on foreign pharmaceutical sources during health emergencies.

Generated by award_classification v2.0.0 via claude-haiku-4-5-20251001 on 2026-05-15. Cost: $0.002218.

Period of performance

Start

2025-09-26

End

2027-09-29

Status

activein 498 days

Recipient

Other awards from this recipient

Sources

USAspending.gov — all awards for this UEI →
SAM.gov entity registration →
Award record ingested from usaspending. Source identifier CONT_AWD_75A50325F80036_7505_36F79723D0219_3600.

The Buildout does not edit federal records. Any inaccuracy reflects the upstream source; it will update here when corrected there.